In addition, nearly all targeted therapy responsive NSCLC patients develop resistance within the first 2 years (Pao & Girard, 2011; Camidge et al., 2014) while efficacy of immunotherapy in some advanced NSCLC patients including those with PD-L1 positive tumors is not much better than standard chemotherapy (Carbone et al., 2017). This evidence concerns the gene CD274 and non-small cell lung carcinoma.